Saturday 17 October 2026
Export ICU’s income statement to Excel — free account
SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, up 814.1% from fiscal 2024. In the quarter to June 2026, revenue grew 82.0%, EPS grew 49.4% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.90
0.16
−5.23%
Follow ICU
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
17.08 | 4.03 | 10.15 | 8.75 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.91) | (1.22) | (5.28) | (5.01) | |
P/B ratio |
1.31 | 0.48 | 1.99 | 3.49 | |
Price to Tangible BV |
1.31 | 0.48 | 1.99 | 3.49 | |
EV/Sales |
4.37 | (3.60) | 5.43 | 6.18 | |
EV/EBITDA |
0.00 | 0.37 | 0.00 | 0.00 | |
EV/Operating CF |
(0.27) | 0.33 | (0.57) | (0.77) | |
EV/FCF |
(0.27) | 0.33 | (0.57) | (0.77) | |
Quick Ratio |
3.44 | 3.26 | 2.41 | 1.65 | |
Current Ratio |
3.66 | 3.63 | 2.73 | 1.89 | |
Net Debt/EBITDA |
3.85 | 3.97 | 2.60 | 1.84 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.09 | 0.13 | 0.15 | 0.20 | |
Operating CF/Net income |
1.11 | 1.41 | 0.78 | 0.80 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | (274.36) | (600.50) | (473.87) | |
Research and Development Expense of Revenue |
1,010.93% | 523.81% | 473.54% | 409.76% | |
Selling, General and Administrative Expense of Revenue |
1,037.16% | 291.90% | 345.05% | 297.89% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
158.47% | 16.67% | 18.38% | (16.10%) | |
Graham Net Nets |
0.72 | 1.98 | 0.47 | 0.26 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(289.47%) | (345.83%) | (129.03%) | (106.54%) | |
Free Cash Flow Yield |
(94.38%) | (273.34%) | (94.04%) | (91.36%) | |
Revenue per Share |
0.07 | 0.20 | 0.13 | 0.15 | |
Operating CF per Share |
(1.46) | (1.97) | (0.70) | (0.73) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.46) | (1.97) | (0.70) | (0.73) | |
Cash per Share |
5.21 | 5.78 | 2.39 | 1.70 | |
Shareholders Equity per Share |
4.34 | 5.02 | 1.87 | 1.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.34 | 5.02 | 1.87 | 1.05 | |
Free Cash Flow |
(3.84) | (4.09) | (2.76) | (2.99) | |
Working Capital |
10.81 | 9.84 | 6.82 | 3.88 | |
Net Current Asset Value |
10.81 | 9.84 | 6.82 | 3.88 | |
EV/EBIT |
0.00 | 0.36 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.14 | 0.17 | 0.14 | 0.21 | |
Average Payables |
2.85 | 2.00 | 2.06 | 1.95 | |
Average Inventory |
— | — | 0.05 | 0.08 | |
Average Assets |
10.06 | 9.41 | 9.43 | 8.52 | |
Average Common Equity |
4.71 | 4.12 | 3.94 | 3.82 |
Columns are period end dates